What question did this study set out to answer?

This research aims to assess the prognostic value of HAVCR2 (TIM-3) in seminoma using various analytical techniques.

HAVCR2 (TIM-3) as a favorable prognostic immune marker in seminoma: Integrative checkpoint screening and tissue validation

View Full Paper

Ask AI

Bookmark

This research aims to assess the prognostic value of HAVCR2 (TIM-3) in seminoma using various analytical techniques.
Applied elastic net–penalized Cox regression on four-gene immune checkpoint panel in TCGA seminoma cohort.
Conducted survival analyses using progression-free interval and validated findings in independent tissue microarray cohort.
Performed pooled analysis incorporating both transcriptomic and protein-level data.
Higher HAVCR2 expression correlated with improved progression-free interval (log-rank p = 0.120) in TCGA cohort.
High TIM-3 expression linked to better relapse-free survival in the TMA cohort (log-rank p = 0.053).
In the pooled cohort, HAVCR2/TIM-3 expression was associated with improved event-free survival (log-rank p = 0.019; HR = 0.201, p = 0.035).

No takes yet. Share an insight, caveat, or question.

Randomized trial evaluates HAVCR2 expression in seminoma, indicating its potential as a favorable immune marker.

Kim et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark